McKesson Corporation

McKesson Corporation

MCK

$1,023.90

Updated: 04/11/2026, 17:07:55

Market Cap
$119.38B
Sector
Healthcare
Industry
Medical - Distribution
Country
US

No historical data available

Company Profile

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

USD
NYSE
CEO: Brian S. Tyler
Employees: 42,300
https://www.mckesson.com
Asset Summaries
Latest generated summaries for MCK

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
MCK-10-k-fy2026.html3.0 MBtext/htmlENFiled 08/05/2026Period ended 31/03/2026

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2026 filing.

Evidence-backed · 63 KPI observations

Revenue

$403.4B

FY 2026 · Reported

Net income

$4.8B

FY 2026 · Reported

Gross margin

3.6%

FY 2026 · Calculated

Free cash flow

$5.7B

FY 2026 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$4.8B

FY 2026 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

North American Pharmaceutical distribution
North American Pharmaceutical segment
Prescription Technology Solutions segment
Oncology & Multispecialty segment
Medical-Surgical Solutions segment and private brand scale
Independent pharmacy and health system solution suites

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Diversified healthcare services leader delivering insights, products, and services to make quality care more accessible and affordable

98%
Source evidence
“We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere.”

New four-segment reporting structure (fiscal 2026)

Four reportable segments effective Q2 fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions

98%
Source evidence
“We implemented a new segment reporting structure commencing in the second quarter of fiscal 2026, which resulted in four reportable segments”

Medical-Surgical Solutions separation and Apollo investment

Medical-Surgical Solutions to be separated into independent company; Apollo Funds to acquire ~13% minority stake via ~$1.25B convertible preferred equity investment (announced April 20, 2026)

98%
Source evidence
“Apollo Funds will acquire approximately 13% minority ownership interest in our Medical‑Surgical Solutions segment through an investment of approximately $1.25 billion in the segment’s convertible preferred equity”

New four-segment structure fiscal 2026

Four reportable segments effective Q2 fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions; Norway in Other

98%
Source evidence
“Commencing in the second quarter of fiscal 2026, we implemented a new segment reporting structure which resulted in four reportable segments”

Oncology & Multispecialty segment

Provider solutions spanning specialty distribution, GPOs, infusion, InspiroGene cell/gene therapy, U.S. Oncology Network, PRISM Vision, SCRI, Ontada

97%
Source evidence
“provider solutions that encompass specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene™ cell and gene therapy services”

North American Pharmaceutical segment performance FY2026

FY2026 operating profit up on higher distribution volumes, $210M LIFO credit; offset by lower antitrust settlement proceeds and prior-year Rite Aid impact

95%
Source evidence
“a LIFO credit of $210 million in fiscal 2026 compared to a charge in the prior year period, and a prior year charge of $57 million related to our estimated liability for opioid-related claims.”

McKesson Canada wholesale business

Canadian business among largest pharmaceutical wholesale/retail distributors in Canada with national distribution center network

95%
Source evidence
“Our Canadian pharmaceutical business is one of the largest pharmaceutical wholesale and retail distributors in Canada.”

Medical-Surgical Solutions performance and planned separation

FY2026 operating profit up; segment has $25M separation-related charges, with a further $52M Corporate charge tied to the planned separation of this segment

95%
Source evidence
“partially offset by $25 million charges related to our planned separation of this segment and a decline in the contribution from our ambulatory care business.”

Oncology & Multispecialty segment performance FY2026

FY2026 operating profit up primarily on specialty pharmaceuticals growth and a $51M net gain on sale of an investment

93%
Source evidence
“primarily due to growth in specialty pharmaceuticals, including contributions from FY26 business acquisitions, a net gain of $51 million related to the sale of an investment and market decisions”

Prescription Technology Solutions demand driver

FY2026 operating profit increased primarily driven by higher demand for access solutions

92%
Source evidence
“Operating profit increased for the year ended March 31, 2026 compared to the prior year primarily driven by higher demand for access solutions.”

GPO and government customer agreements

Agreements with GPOs acting as purchasing agents for hospitals, pharmacies, and other providers, and with government entities; receivables held by individual GPO members

95%
Source evidence
“We also have agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies, and other healthcare providers, as well as with government entities and agencies.”

Medical-Surgical end markets and customers

Medical-Surgical serves non-acute/alternate-site U.S. providers across ambulatory care, extended care, government, and online marketplaces/retailers

95%
Source evidence
“We partner with manufacturers and channel partners to support our key markets, including ambulatory care, extended care, government, and other online marketplaces, and retailers.”

North American Pharmaceutical distribution

Distributes branded, generic, specialty, biosimilar and OTC drugs in U.S. and Canada; also financial, operational, and clinical solutions to pharmacies

98%
Source evidence
“distributes branded, generic, specialty, biosimilar and over-the-counter (“OTC”) pharmaceutical drugs, and other healthcare-related products to customers in the United States (“U.S.”) and Canada”

North American Pharmaceutical segment

Distribution/logistics of branded, generic, specialty, biosimilar, and OTC pharmaceuticals in the U.S. and Canada plus pharmacy solutions and services

97%
Source evidence
“North American Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs”

Prescription Technology Solutions segment

Technology services addressing medication access, affordability, and adherence, plus 3PL and wholesale distribution support for biopharma customers

97%
Source evidence
“Prescription Technology Solutions offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, and patient enrollment”

Oncology & Multispecialty segment

Provider solutions spanning specialty distribution, U.S. Oncology Network, InspiroGene cell & gene therapy, Ontada data, PRISM Vision, and Sarah Cannon Research Institute

97%
Source evidence
“the segment supports the U.S. Oncology Network, one of the largest networks of physician-led, integrated, community-based oncology practices”

Medical-Surgical Solutions segment and private brand scale

Medical-surgical/lab/pharma distribution to U.S. non-acute providers; own line of more than 4,000 private-brand products

96%
Source evidence
“This segment offers national brand medical-surgical products as well as our own line of more than 4,000 high-quality products”

Independent pharmacy and health system solution suites

Solution suites for independent pharmacies (OneStop Generics, Pinpoint, FrontEdge, RxOwnership) and institutional/health-system providers (advisory, Plasma and Biologics, 340B, Supply Assurance, pharmacy software)

93%
Source evidence
“McKesson Pharmacy Systems, MacroHelix, and Supply Logix, all of which provide innovative software technology and services that support retail pharmacies and hospitals”

Operations and dependencies

Supplier concentration

Largest supplier 11% of total purchases; ten largest suppliers ~71% of total purchases in fiscal 2026

97%
Source evidence
“We obtain pharmaceutical and other products from manufacturers and our largest supplier accounted for 11% of our total purchases in fiscal 2026... The ten largest suppliers in fiscal 2026 accounted for approximately 71% of our total purchases.”

ClarusONE generic sourcing JV with Walmart

Sources generic pharmaceutical drugs through ClarusONE Sourcing Services LLP joint venture with Walmart Inc.

97%
Source evidence
“We also source generic pharmaceutical drugs through our ClarusONE Sourcing Services LLP joint venture with Walmart Inc. (“ClarusONE”)”

Employee counts by geography

More than 43,000 employees worldwide as of March 31, 2026 (1,400 part-time); ~38,000 U.S., 5,000 Canada, 400 rest of world; supplemented by contractors/consultants

97%
Source evidence
“As of March 31, 2026, we had more than 43,000 employees worldwide, which includes 1,400 part-time employees.”

Positioning and strategy

PRISM Vision Holdings acquisition

Acquired 80% controlling interest in PRISM Vision (ophthalmology/retina administrative services) for $875 million cash on April 1, 2025

98%
Source evidence
“We acquired an 80% interest in PRISM Vision for $875 million in cash, and prior owners, including management and physicians in PRISM Vision practices, retained a 20% ownership interest.”

Core Ventures acquisition

Acquired 70% of Core Ventures (Florida Cancer Specialists services organization) for $2.5 billion cash on June 2, 2025

98%
Source evidence
“We acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash and FCS physicians retained a 30% ownership interest.”

Scale and portfolio breadth as advantage

Scale and breadth of product/service portfolio are key competitive advantages; primary factors include price, service quality, assortment, innovation, emerging technology adoption

93%
Source evidence
“We believe that our scale and the breadth of our product and service portfolio are key competitive advantages.”

Primary distribution competitors

Primary competitors in distribution, wholesaling, and logistics are Cencora, Inc. and Cardinal Health, Inc.; markets highly competitive with significant consolidation

98%
Source evidence
“Our primary competitors in distribution, wholesaling, and logistics are Cencora, Inc. and Cardinal Health, Inc.”

Norway disposal group sale

Completed sale of Norway disposal group on January 30, 2026 for $821 million; recorded net gain of $480 million

97%
Source evidence
“On January 30, 2026, we completed the sale of our Norway disposal group for an adjusted purchase price of $821 million. We recorded a net gain of $480 million”

Sale of Norway business completed

Completed sale of former Norwegian distribution and retail pharmacy businesses during fiscal 2026

97%
Source evidence
“During fiscal 2026, we completed the sale of our businesses in Norway.”

Norway and Canadian retail divestitures

Completed sale of Norway disposal group in fiscal 2026 and Canadian retail disposal group in fiscal 2025

95%
Source evidence
“We completed the sale of our Norway disposal group and our Canadian retail disposal group in fiscal 2026 and 2025, respectively.”

Medical-Surgical Solutions separation with Apollo minority investment

Planned separation of Medical-Surgical Solutions; Apollo Funds to invest ~$1.25 billion for ~13% minority stake in convertible preferred equity

98%
Source evidence
“funds managed by affiliates of Apollo Global Management, Inc. (“Apollo Funds”) will acquire approximately 13% minority ownership interest in our Medical‑Surgical Solutions segment through an investment of approximately $1.25 billion”

AI and data/analytics investment

Invests in distribution centers, automation, and data/analytics; early stages of exploring AI capabilities to improve productivity and enhance products/services

94%
Source evidence
“We are in the early stages of exploring potential AI capabilities and related data and analytics across our enterprise to improve productivity and efficiency”

Risks, financing, and outlook

May 2025 public notes offering to fund Core Ventures

$2.0 billion notes offering (4.65% due 2030, 4.95% due 2032, 5.25% due 2035) to fund Core Ventures acquisition

97%
Source evidence
“we completed a public debt offering of 4.65% Notes due May 30, 2030 in a principal amount of $650 million, 4.95% Notes due May 30, 2032 in a principal amount of $650 million, and 5.25% Notes due May 30, 2035 in a principal amount of $700 million”

Post-year-end Medical-Surgical segment credit agreement

Medical-Surgical subsidiaries entered $750M term loan due 2031, $250M term loan due 2028, and $1.0B revolver due April 2031 (net proceeds $993M)

95%
Source evidence
“a $750 million principal senior secured term loan due in 2031 and a $250 million principal senior secured term loan due in 2028, for total proceeds received, net of discounts and debt offering expenses, of $993 million”

Controlled substances regulatory oversight

Subject to DEA, FDA, HHS, CMS and state pharmacy board standards; must hold valid DEA and state registrations and comply with the Controlled Substances Act

95%
Source evidence
“we are required to hold valid DEA and state-level registrations and licenses, meet various security and operating standards, and comply with the Controlled Substances Act”

Supplier/product supply disruption risk

Relies on third parties for pharmaceutical supply; disruptions from sanctions, tariffs, labor disputes, natural disasters, and pandemics may materially harm results

96%
Source evidence
“We rely on third parties for the supply of pharmaceutical and other products, and our operations are subject to our suppliers' continued ability to supply the products that we require.”

Generic pharmaceuticals distribution risk

Generic distribution subject to availability and pricing risks; ClarusONE sourcing may fail; patent infringement claims may not be fully indemnified

95%
Source evidence
“Input cost increases, product discontinuations, and market shortages could result in ClarusONE being unsuccessful in sourcing product to meet the needs of our customers, or could negatively impact our margin.”

Healthcare reform and reimbursement risk

Healthcare reform including the IRA, OBBBA, Executive Order 14297, CMS rulemaking, 340B litigation, and state drug pricing laws could reduce margins and create uncertainty

94%
Source evidence
“These include: the IRA; the OBBBA; Executive Order 14297; CMS rulemaking on BFSFs and proposed rebate models; 340B program litigation and developments; and state drug pricing legislation.”

Capital and credit markets access risk

Credit rating downgrades could limit debt market access, raise borrowing costs, and lead to more restrictive covenants; products sold under short-term unsecured credit

94%
Source evidence
“any downgrades in our credit ratings might limit our access to public debt markets, decrease the willingness of financial institutions to lend to us, lead to more restrictive debt covenants, increase our borrowing costs, and adversely affect our earnings.”

Inflation, recession, and currency risk

Exposed to inflation, recession, and FX risk from non-USD operations, intercompany loans, and substantial international net assets

94%
Source evidence
“Our non-U.S. operations, import and export of products sold in currencies other than U.S. dollar (non-USD), non-USD intercompany loans, and our substantial international net assets also expose us to foreign currency exchange rate risk.”

AI adoption risks

Increasing reliance on AI technologies in internal operations introduces risks of inaccurate outputs, performance degradation, third-party tool vulnerabilities, and data/IP compromise

93%
Source evidence
“We increasingly rely on technologies powered by or incorporating AI in our internal operations and business processes. The use of AI technologies introduces risks and uncertainties.”

Antitrust/competition law exposure on strategic transactions

FTC and DOJ enforcement of competition laws in healthcare; strategic transactions may require review; possible restrictions on vertical integration of physician practice management and pharmaceutical distribution

90%
Source evidence
“Enforcement of competition laws in the healthcare industry remains a focus of the FTC and the U.S. Department of Justice. Some of our strategic transactions may require review by competition regulators”

Climate change regulation cost risk

New or expanded climate policies could impose costs including capex for reporting systems, attestations, and GHG reduction measures; timing/extent uncertain

90%
Source evidence
“New or expanded climate-related policies and laws could impose costs on us, including capital expenditures to develop or modify data gathering and reporting systems, third-party attestations, and additional GHG reduction measures.”

Material exposure graph

CVS Health Corporation
Customer Exposure

CVS is McKesson's largest customer at ~24% of revenues and ~21% of trade receivables; partnership runs to June 2027, concentrated in the North American Pharmaceutical segment.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2026.”
United States
Revenue Exposure

Core pharmaceutical distribution, RxTS, and Medical-Surgical businesses operate in the U.S.; ~38,000 of 43,000+ employees are U.S.-based.

Relevance 95·Dependency 90·Confidence 97
Source evidence
“We had approximately 38,000 employees in the U.S., 5,000 employees in Canada, and 400 employees in the rest of the world.”
CVS Health Corporation
Customer Exposure

CVS Health is McKesson's largest customer at ~24% of consolidated revenues and ~21% of trade receivables; loss or payment default would be materially adverse.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“A material default in payment, a material reduction in purchases from GPOs or any other large customers, or the loss of a large customer or GPO could have a material adverse impact on our financial position, results of operations, and liquidity.”
pharmaceutical and other products from manufacturers
Supplier Dependency

Top-10 suppliers are ~71% of purchases; supplier loss and manufacturer pricing/consolidation materially affect supply and gross margin.

Relevance 90·Dependency 88·Confidence 95
Source evidence
“The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable.”
Pharmaceutical products
Supplier Dependency

McKesson relies on third-party suppliers for pharmaceutical products; supplier failures from regulatory, raw material, manufacturing, or geopolitical causes can materially disrupt operations.

Relevance 90·Dependency 85·Confidence 96
Source evidence
“We rely on third parties for the supply of pharmaceutical and other products, and our operations are subject to our suppliers' continued ability to supply the products that we require.”
Biopharma companies
Customer Exposure

Prescription Technology Solutions provides logistics, dispensing support, and technology services to biopharma customers across the product lifecycle.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle”
Controlled Substances Act / DEA regulation
Regulatory Exposure

Pharmaceutical distribution requires DEA/state registrations, security standards, and costly controlled-substance monitoring programs.

Relevance 85·Dependency 75·Confidence 93
Source evidence
“We maintain extensive controlled substance monitoring and reporting programs at considerable expense in order to help us meet those standards.”
IRA / healthcare reform (OBBBA, 340B, drug pricing laws)
Regulatory Exposure

Healthcare reform (IRA, OBBBA, CMS rulemaking, 340B litigation, state drug pricing) could reduce reimbursement and distribution economics.

Relevance 85·Dependency 70·Confidence 92
Source evidence
“certain changes in reimbursement methodologies (including government rates) for pharmaceuticals, medical treatments, and related services reduce profit margins for us and our customers”
Cencora, Inc.
Competitive Exposure

Cencora is a named primary competitor in pharmaceutical distribution, wholesaling, and logistics.

Relevance 85·Dependency 60·Confidence 97
Source evidence
“Our primary competitors in distribution, wholesaling, and logistics are Cencora, Inc. and Cardinal Health, Inc.”
Cardinal Health, Inc.
Competitive Exposure

Cardinal Health is a named primary competitor in distribution and also competes in Oncology & Multispecialty via combined distribution/GPO/provider capabilities.

Relevance 85·Dependency 60·Confidence 97
Source evidence
“Certain competitors also offer combinations of distribution, GPO, and provider services capabilities, including Cencora, Inc. and Cardinal Health, Inc.”
Generic pharmaceuticals
Supplier Dependency

Generic distribution business exposed to product availability and pricing risks; ClarusONE sourcing failures or input cost increases could hurt margins; patent infringement claims may not be fully indemnified.

Relevance 80·Dependency 75·Confidence 95
Source evidence
“Our generic pharmaceuticals distribution business is subject to both product availability and pricing risks.”
Group purchasing organizations (GPOs)
Customer Exposure

GPOs function as purchasing agents for member hospitals and pharmacies; top-10 customers (incl. GPOs) represent ~73% of revenues, creating significant sales and credit concentration.

Relevance 80·Dependency 70·Confidence 95
Source evidence
“We also have agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies.”
GPOs and government entities
Revenue Exposure

GPOs act as purchasing agents for hospitals, pharmacies, and providers; government contracts carry funding and compliance risks affecting demand.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“each of which functions as a purchasing agent on behalf of member hospitals, pharmacies, and other healthcare providers, as well as with government entities and agencies”
U.S. non-acute healthcare providers
Customer Exposure

Medical-Surgical Solutions distributes to U.S. providers in ambulatory and extended care settings.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“provides medical-surgical, laboratory, and pharmaceutical distribution, logistics, and other services to U.S. healthcare providers operating in the non-acute settings”
Biopharma and life sciences partners
Customer Exposure

RxTS serves biopharma/life sciences partners with 650+ brand connections, generating medication access, affordability, and adherence service revenue.

Relevance 75·Dependency 60·Confidence 93
Source evidence
“has supported over 650 biopharma brands representing most therapeutic areas”
Inflation
Cost Driver

Inflation raises operating and inventory purchase costs and reduces consumer commercial spending; compounded by supply chain disruptions, labor tightness, tariffs, and interest rates.

Relevance 70·Dependency 60·Confidence 94
Source evidence
“Inflationary conditions result in increased costs associated with our normal business operations and decreased levels of consumer commercial spending”
Regulatory approvals for Apollo Medical-Surgical investment
Regulatory Exposure

The ~$1.25B Apollo Funds convertible preferred investment in Medical-Surgical Solutions is subject to regulatory approvals and customary closing conditions.

Relevance 70·Dependency 55·Confidence 95
Source evidence
“This transaction closing is subject to regulatory approvals and customary closing conditions.”
Florida Cancer Specialists & Research Institute (FCS)
Revenue Exposure

McKesson acquired 70% of Core Ventures, the business and administrative services organization established by FCS, expanding its oncology platform.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC, (“FCS”). We acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash”
ClarusONE (JV with Walmart Inc.)
Supplier Dependency

Generic drug sourcing for U.S. pharmaceutical distribution runs through the ClarusONE JV with Walmart, a key supply arrangement.

Relevance 62·Dependency 45·Confidence 95
Source evidence
“We also source generic pharmaceutical drugs through our ClarusONE Sourcing Services LLP joint venture with Walmart Inc.”
Canada
Revenue Exposure

North American Pharmaceutical includes Canadian wholesale and retail distribution operations, one of the largest in Canada.

Relevance 60·Dependency 50·Confidence 95
Source evidence
“Our Canadian pharmaceutical business is one of the largest pharmaceutical wholesale and retail distributors in Canada.”
AI technologies
Technology Dependency

McKesson relies increasingly on AI in internal operations and business processes; third-party AI tools and data rights affect data services growth and AI objectives.

Relevance 60·Dependency 50·Confidence 90
Source evidence
“Reliance on third-party AI tools and solutions may expose us to risks that are outside of our control, including compliance gaps.”
Competition/antitrust law enforcement
Legal Exposure

FTC/DOJ enforcement and potential restrictions on vertical healthcare ownership could delay or block strategic transactions central to the growth strategy.

Relevance 55·Dependency 45·Confidence 88
Source evidence
“Some of our strategic transactions may require review by competition regulators, with potential delays or other unfavorable outcomes.”
OECD Pillar Two global minimum tax
Tax Exposure

Pillar Two introduces a 15% country-by-country global minimum tax; McKesson concluded no expected material impact, but ultimate effect may differ from estimates.

Relevance 55·Dependency 40·Confidence 93
Source evidence
“While we evaluated the implications of these measures and concluded that they are not expected to have a material impact on our consolidated financial position, results of operations, or cash flows, their ultimate impact may differ from our estimates.”
Artificial intelligence
Demand Driver

Company invests in data and analytics supporting growth priorities including AI to improve productivity and enhance products and services.

Relevance 55·Dependency 35·Confidence 90
Source evidence
“we invest in data and analytics to support our growth priorities, including artificial intelligence (“AI”)”
Full company information
Latest profile, trading, valuation, and identifier data stored for MCK.
Share price
$1,023.90
Market cap
$119.38B
Exchange
NYSE
Currency
USD
CEO
Brian S. Tyler
Employees
42,300
IPO date
10/11/1994
Beta
0.279
Last dividend
$0.00
Day range
$1,005.00 – $1,026.22
52-week range
$723.68 – $1,030.27
1-day performance
2.43%
1-year performance
41.48%
Current drawdown (1Y)
-0.62%
CIK
0000927653
CUSIP
58155Q103
ISIN
US58155Q1031
Created
07/12/2025, 05:11:32
Last update
04/11/2026, 17:07:55

Track McKesson Corporation with an AI analyst

See which prediction-market events move MCK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to MCK from your Railway `news_articles` table.

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research • STOCK • 10/06/2026, 12:01:24

Why McKesson (MCK) is a Top Momentum Stock for the Long-Term

Zacks Investment Research • STOCK • 08/06/2026, 12:51:21

McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research • STOCK • 27/05/2026, 12:00:26

Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

Zacks Investment Research • STOCK • 22/05/2026, 15:21:07

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research • STOCK • 14/05/2026, 12:01:34

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 17:10:48

McKesson Q4 Earnings Call Highlights

MarketBeat • STOCK • 11/05/2026, 17:09:43

MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up

Zacks Investment Research • STOCK • 08/05/2026, 13:51:07

McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 07/05/2026, 23:01:17

Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics

Zacks Investment Research • STOCK • 07/05/2026, 21:01:13

McKesson (MCK) Surpasses Q4 Earnings Estimates

Zacks Investment Research • STOCK • 07/05/2026, 20:55:12

Should You Buy, Sell, or Hold McKesson Before Q4 Earnings?

Zacks Investment Research • STOCK • 07/05/2026, 16:35:45